CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 660 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Pregabalin 150-600 mg/day (BID) or Lamotrigine 100-500 mg/day (BID)AI-extracted
Key inclusion· 3
  • Diagnosed with partial epilepsy
  • At least 2 partial seizures in the past year
  • One seizure within the past 6 months
Key exclusion· 2
  • Treatable causes of seizures (metabolic, neoplastic, or active infectious etiology)
  • Primary generalized seizures

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00280059
NCT00280059Phase 3Completed

A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jan 20, 2006·Updated Jan 28, 2021

In Brief

A Phase 3 clinical trial evaluating Pregabalin and Lamotrigine for Epilepsy, Partial. Completed, enrolled 660 participants across 102 sites in 29 countries.

Detailed Summary

The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Bulgaria, China, Colombia, Czechia, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Portugal, Romania, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 20, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2009
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.4 years ago

Interventions

Pregabalindrug

dose 150-600 mg/day given BID

Lamotriginedrug

dose 100-500 mg/day given BID